Xencor 10-Q: Q3 Swings to $39.4M Profit on $116.5M Revenue; $555.7M Cash Funds Operations Into 2029
XNCR has more than doubled off its 52-week low of $10.375.
Summary
Xencor's Q3 2026 10-Q shows a $39.4 million profit ($0.50 diluted EPS) on $116.5 million of revenue, driven by the $105 million Alexion settlement and a $25 million Astellas milestone, with $555.7 million of cash funding operations into 2029.
Key Events · Earnings and Guidance · XNCR
-
Q3 Swings to $39.4M Profit
Net income attributable to Xencor was $39.4 million, or $0.50 per diluted share, versus a $6.0 million loss ($0.08) a year earlier, on revenue of $116.5 million versus $21.0 million.
-
Profit Driven by One-Time Items
The quarter included $77.4 million of Alexion settlement consideration recognized as royalty revenue plus a $25.0 million Astellas milestone; the nine-month net loss was still $111.2 million ($1.47 per share).
-
Cash of $555.7M, Runway Into 2029
Cash, cash equivalents and marketable debt securities totaled $555.7 million at September 30, 2026 versus $610.8 million at December 31, 2025; management expects $480-500 million at year-end with funding into 2029.
-
$200M ATM Still Untouched
The February 2023 sales agreement with Leerink for up to $200.0 million of common stock remains unused — no shares have been issued under it as of September 30, 2026.
Analysis · XNCR · Life Sciences
The 10-Q puts hard numbers behind the same-day earnings release. Revenue of $116.5 million versus $21.0 million a year ago flipped Q3 to $39.4 million of net income ($0.50 diluted EPS), but the driver was one-time items — the $105.0 million Alexion royalty settlement (of which $77.4 million landed in Q3) plus a $25.0 million Astellas milestone — not recurring product sales. The nine-month picture is still a $111.2 million net loss, and R&D spending rose to $84.3 million in the quarter from $54.4 million as the pipeline advances. With cash and marketable debt securities of $555.7 million, management guiding to $480-500 million at year-end and funding into 2029, there is no near-term financing need — and the $200 million ATM with Leerink remains completely unused, so it poses no dilution overhang today.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XNCR was trading at $36.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $10.38 to $35.05. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.